Pfizer (PFE) is back in focus for investors as its latest reported figures offer a snapshot of how the US$143.7b ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell.

Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

Eli Lilly & Company LLY and Pfizer PFE are large-cap U.S. drugmakers supported by broad product portfolios and strong ...

Track Pfizer share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, shareholding, financial reports, annual & quarterly results, and profit & loss ...

Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product and patent cliff challenges could prevent a big bounce this year. Even if ...

I last covered Pfizer Inc. stock (NYSE:PFE) on Feb 19. The article rated the stock as hold after examining its FQ4 earnings report (ER) and dividend declarations. Since then, a few new catalysts have ...

Pfizer announced that Chief Financial Officer Dave Denton will leave the company in August to pursue an external opportunity.

Pfizer offers a 6.3% yield, but its high dividend reflects weak growth prospects and looming patent cliffs. PFE’s dividend is currently covered by cash flow, but payout ratios are stretched, and ...

Pfizer (NYSE:PFE) will release its quarterly earnings report on Tuesday, 2026-02-03. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Pfizer to report an earnings ...